AstraZeneca officially opened its new $1 billion research and development center in Kendall Square, Cambridge, on Monday, marking a major expansion of its presence in the region. The 18-story facility, located at 290 Binney Street, encompasses approximately 570,000 square feet and will house up to 1,100 employees by the end of the year. This investment is part of AstraZeneca’s broader commitment to increase its operations in the United States, aiming to spend $50 billion domestically by 2030 and expand its Massachusetts workforce by more than 50 percent to 3,000 employees in the coming years.
The global pharmaceutical company, headquartered in Cambridge, England, unveiled the new center amidst a backdrop of a recovering biotech sector, which had faced a slowdown in private investment and reduced federal funding in the post-pandemic period. The facility will support research across all of AstraZeneca’s therapeutic areas, including oncology, chronic conditions such as chronic obstructive pulmonary disease, and rare diseases. It features 10 interconnected laboratory floors equipped with advanced technologies, including automated systems and artificial intelligence, designed to accelerate drug discovery and development.
At the ribbon-cutting event, AstraZeneca CEO Pascal Soriot emphasized the importance of the company’s ongoing investment in the Massachusetts life sciences ecosystem, calling it “one of the world’s greatest life science centers.” He highlighted the collaboration between public and private sectors as critical to maintaining the region’s competitive edge in biology and medicine.
Massachusetts Governor Maura Healey praised the new facility’s potential to bolster the state’s economy and its ability to attract and keep top scientific talent. She acknowledged the global competition facing the state’s biotech industry, pointing specifically to China’s rapid growth in scientific research capacity. Healey stressed the need for a concerted effort to sustain Massachusetts’ position in the global life sciences landscape.
Sharon Barr, AstraZeneca’s executive vice president of biopharmaceutical research and development, acknowledged China as both a competitor and collaborator in medical innovation. Barr pointed to Massachusetts hospitals’ participation in more than a quarter of the company’s over 200 clinical trials last year as an example of the company’s deep local engagement.
The new facility’s laboratories include cutting-edge automation, with robotic systems handling routine tasks such as pipetting, some playfully named after popular culture characters. The “lab of the future” concept integrates continuous biologics research powered by AI and robotics, enabling researchers to rapidly identify and test potential drug candidates. Puja Sapra, head of research and development for biologics engineering and oncology targeted delivery, noted that automation was built into the design from the ground up, a process more efficient than retrofitting existing lab spaces.
With this expansion, AstraZeneca aims to enhance its research capabilities significantly, supporting innovation and growth in one of the world’s leading biotech hubs.